Key Insights• According to the research report, "Saudi Arabia Diabetes Care Devices Market Outlook, 2031," published by Actual Market Research, the Saudi Arabia Diabetes Care Devices Market is anticipated to add to more than 188.46 Million by 2026-31.• The Saudi Arabia diabetes care devices market is undergoing a major structural shift driven by the Health Sector Transformation Program under Saudi Vision 2030. Through the Ministry of Health (MOH) and the transformation of public healthcare delivery into autonomous health clusters, state authorities have implemented aggressive national screening programs for non-communicable diseases (NCDs). A strategic breakthrough includes the widespread integration of continuous glucose monitoring (CGM) systems into Ministry of Health tenders, the National Unified Procurement Company (NUPCO) supply chain, and military healthcare networks. This centralized public procurement allows eligible citizens living with Type 1 diabetes and severe insulin-dependent Type 2 diabetes to receive factory-calibrated CGMs (such as Dexcom G7 and Abbott FreeStyle Libre 3) and automated closed-loop systems free of charge at point-of-care, drastically reducing traditional reliance on self-monitoring blood glucose (SMBG) finger-stick meters.• Saudi Arabia's market is rapidly adopting automated insulin delivery (AID) technologies, supported by progressive clearances from the Saudi Food and Drug Authority (SFDA). Major technological breakthroughs implemented in top-tier medical centers such as King Faisal Specialist Hospital & Research Centre and King Fahad Medical City include the clinical deployment of tubeless patch pumps and interoperable closed-loop algorithms (e.g., Medtronic MiniMed 780G, Tandem Control-IQ, and Insulet Omnipod 5).• Crucially, an estimated 43.6% of the adult cases (over 2.33 million individuals) remain formally undiagnosed, while another 3.79 million adults present with Impaired Fasting Glucose (IFG). Type 1 diabetes affects over 222,000 individuals across the Kingdom, including more than 46,000 children and adolescents under age 20.

From an economic perspective, total direct annual diabetes-related healthcare expenditure in Saudi Arabia exceeds $7.33 billion USD (over 27.5 billion SAR), with average per-person annual medical spending for diabetes management reaching $1,372 USD.Market Outlook• The prospective landscape for diabetes care devices in Saudi Arabia is defined by the expansion of direct-to-consumer (DTC) pharmacy e-commerce networks and national digital health integration. Major retail pharmacy chains (such as Nahdi Medical Company and Al-Dawaa Pharmacies) serve as primary fulfillment networks, leveraging e-pharmacy platforms to distribute over-the-counter continuous biosensors, smart insulin pen caps, and glucometer consumables directly to patients. Concurrently, the Ministry of Health is linking wearable device outputs with the national Sehhaty digital health portal and regional EMR systems.• While public health programs guarantee high commercial volume, medical technology providers operating in Saudi Arabia must navigate strict pre-market clearance standards, local clinical data requirements, and cybersecurity compliance enforced by the Saudi Food and Drug Authority (SFDA), alongside centralized price negotiations managed by NUPCO for state health clusters. Clinical guidelines, scientific research, and professional training standards are directed by leading bodies, including the Saudi Diabetes Society (SDS), the Saudi Endocrine Society (SES), and the Saudi Association of Diabetes Educators (SADE). Leading international and regional companies actively driving the commercial marketplace in Saudi Arabia include Abbott Laboratories Saudi Arabia, Dexcom, Medtronic Saudi Arabia, Roche Diabetes Care, Insulet Corporation, Sanofi, Novo Nordisk, and Ascensia Diabetes Care.Market DynamicsDriver: High national prevalence and centralized public funding via NUPCO and vision 2030The primary growth driver for the Saudi Arabian diabetes care devices market is the country's exceptionally high disease prevalence combined with massive, centralized state funding. Saudi Arabia has one of the highest diabetes prevalence rates globally, affecting over 23% of the adult population.

To combat this public health challenge, the Saudi government, under the Vision 2030 Health Sector Transformation Program, heavily subsidizes diabetes management equipment. Centralized public procurement managed by the National Unified Procurement Company (NUPCO) purchases continuous glucose monitoring (CGM) systems, insulin pumps, and test supplies in bulk for distribution across Ministry of Health (MOH) hospitals, military medical centers, and university health clusters. Challenge: High expatriate out-of-pocket costs and regulatory SFDA complianceDespite extensive public funding for citizens, market growth encounters barriers within the expatriate workforce segment, private health insurance limitations, and strict regulatory standards. Expatriates comprise a significant portion of Saudi Arabia's population and rely on private health insurance regulated by the Council of Health Insurance (CHI). Private insurance policies vary widely in tiering; while executive plans cover advanced CGMs and automated pumps, basic employer-sponsored packages often restrict coverage to traditional finger-stick blood glucose meters and manual insulin syringes, forcing expatriate patients to pay out-of-pocket for advanced wearables.Trend: Deep e-pharmacy integration (Nahdi/Al-Dawaa) A major trend transforming the Saudi market is the rapid shift toward direct-to-consumer retail e-commerce channels paired with government digital health integration. Dominant retail pharmacy chains such as Nahdi Medical Company and Al-Dawaa Pharmacies have built robust e-pharmacy and mobile application ecosystems that deliver factory-calibrated continuous biosensors, smart insulin pen accessories, and glucometer consumables directly to patients' homes. Concurrently, device manufacturers are pairing continuous monitoring hardware with mobile health software that syncs with the Ministry of Health’s national Sehhaty health app and regional Health Cluster Electronic Medical Record (EMR) portals.Segment Analysis Saudi Arabia Diabetes Care Devices By Product Type• Saudi Arabia’s blood glucose monitoring systems market combines conventional glucometers and test strips with continuous glucose monitoring (CGM) technologies.

A distinctive feature is the importance of consumable quality, affordability, and user education alongside measurement accuracy. The Saudi Food and Drug Authority has highlighted the need for better patient awareness when selecting monitoring devices and using them correctly. Smartphone-connected monitoring, Arabic-language interfaces, and remote data sharing can further support patients and clinicians in reviewing glucose trends. Manufacturers can differentiate themselves through reliable strip and sensor availability, clear device instructions, and responsive customer support.• Saudi Arabia’s insulin delivery devices market includes syringes, insulin pens, insulin pumps, and automated insulin delivery systems. A key market characteristic is the growing clinical focus on integrating insulin delivery with continuous glucose monitoring to support individualized treatment. The national diabetes digital health guidance identifies insulin pumps and CGM systems as important technologies in modern diabetes management.

Device adoption therefore depends not only on hardware performance but also on compatibility, patient eligibility, training, and ongoing access to infusion sets and other consumables. Saudi Arabia Diabetes Care Devices By Disease Type• Saudi Arabia’s type 1 diabetes segment requires consistent insulin administration and frequent glucose monitoring, creating a strong clinical role for CGM systems, insulin pumps, and automated insulin delivery technologies. Integrated devices can help users respond to changing glucose levels and reduce the burden of frequent treatment decisions. Pediatric care is an important application area, where wearable comfort, caregiver alerts, school routines, and accessible training can influence device suitability.• Saudi Arabia’s type 2 diabetes segment requires a broad range of monitoring and delivery solutions because treatment needs vary from lifestyle management and oral medication to insulin therapy. Conventional glucose meters remain practical for targeted testing, while CGM can provide additional insight into glucose responses to food, exercise, and medication for appropriately selected patients. The Saudi market’s emphasis on digital healthcare creates opportunities for connected monitoring platforms that help clinicians review glucose patterns and adjust treatment plans. However, usability, recurring consumable costs, and patient understanding remain important adoption considerations. Saudi Arabia Diabetes Care Devices By End User • Saudi Arabia’s home and self-care segment is shaped by the increasing availability of connected glucose monitoring and insulin delivery technologies.

Patients use glucometers, test strips, wearable sensors, insulin pens, and pumps according to their treatment requirements and access to care. Smartphone connectivity and remote data sharing can help users communicate glucose patterns to healthcare professionals and caregivers, supporting ongoing management between appointments. A distinctive opportunity lies in improving patient confidence through Arabic-language instructions, practical device demonstrations, and accessible technical support.• Hospitals are important users of diabetes care devices in Saudi Arabia, supporting inpatient glucose monitoring, insulin administration, treatment adjustment, and patient education. Their requirements include reliable measurements, clinical workflow compatibility, staff training, and adherence to institutional safety procedures. Hospitals and specialist diabetes teams also influence the introduction of advanced technologies by assessing patient suitability for CGM and insulin pump therapy. The SFDA’s device authorization and safety-monitoring framework makes regulatory compliance and clear product documentation essential considerations for suppliers.• Saudi Arabia’s diagnostic centers support diabetes screening, follow-up testing, and assessment of glycemic control.

Their priorities include consistent testing procedures, reliable equipment, quality assurance, and efficient patient processing. Laboratory-based assessments complement home glucose monitoring by providing clinicians with information to evaluate longer-term glycemic control alongside daily readings. Diagnostic centers can strengthen their role by coordinating reports with primary-care physicians, endocrinologists, and specialist diabetes clinics. For equipment suppliers, dependable servicing, straightforward operation, and integration with laboratory information systems are important differentiators.• Saudi Arabia’s ambulatory surgical centers require diabetes care devices that support appropriate glucose assessment and treatment coordination around outpatient procedures. Their priorities include dependable readings, rapid access to results, hygienic device handling, and clear documentation for perioperative teams. Patients may arrive using personal glucose meters, CGM sensors, insulin pens, or insulin pumps, making it important for staff to understand existing treatment arrangements and follow suitable device-management protocols.

Manufacturers can address this segment through compact monitoring systems, clear operating instructions, and training that helps clinical teams coordinate diabetes management with procedural care.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Diabetes Care Devices Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product Type• Blood Glucose Monitoring Systems• Insulin Delivery DevicesBy Disease Type• Type 1 Diabetes• Type 2 DiabetesBy End User• Home/Self-Care• Hospitals• Diagnostic Centers• Ambulatory Surgical Centers.